Scioto Biosciences was founded in 2017 as a partnership between Monon Bioventures and The Research Institute at Nationwide Children’s Hospital. Together, we are working to advance the rapidly-growing microbiome field by introducing innovative treatment delivery mechanisms.
NEC Society does not endorse any product or company, and does not create, sponsor, or authorize the content of any communications, surveys, programs, or incentives from any company. NEC Society is a registered word mark of its owner and its use does not imply any affiliation, endorsement, or sponsorship by them.
SB-121 is one of the most exciting programs in the microbiome space. Scioto’s Phase Ib in patients with Autism is an excellent proof-of-concept and an enormous step forward. We are thrilled with the potential impact Scioto may have on the lives of patients and caregivers.
– Jisoo Pae, CEO/Founder Genome and Company